Search results (251)
« Back to NewsAgile start-ups partner with academics to find COVID-19 solutions
14 July 2020
Three companies at Oxford’s BioEscalator are developing new detection methods and have discovered potential therapeutics in the fight against COVID-19.
MiroBio graduates From the BioEscalator
1 July 2020
Rapidly growing immune cell regulation company relocates to The Oxford Science Park
Ervaxx rebrands as Enara Bio
22 June 2020
Ervaxx rebrands as Enara Bio to reflect a broader emphasis on the discovery and development of novel TCR-based cancer immunotherapies.
Theolytics announced winners of the Santander Pitch Finale
22 June 2020
The BioEscalator celebrated the success of its recent Pitch Finale event as Theolytics emerged as the winner, securing a spot in the final of BIO International Start-up Stadium.
Base Genomics raises $11M
2 June 2020
Base Genomics announces the company's launch with $11M to commercialise epigenetic technology for early and sensitive cancer detection from a liquid biopsy.
Introducing MediMab Biotherapeutics
26 May 2020
MediMabBio, an immuno-oncology development company, has established a base at the BioEscalator and will expand R&D through collaborative research with local researchers.
Herbicide resistance crisis targeted by new Oxford tech firm MoA Technology
20 October 2019
MoA Technology, borne out of Oxford University research, launches to confront the global herbicide resistance crisis. The Company launches with £6.3m Series A funding round.
Theolytics Limited comes out of stealth mode with Dr Ken Powell announced as Chair of the Board
25 June 2019
Virology spinout Theolytics emerges from stealth with £2.5m seed and Dr Ken Powell as chair.
The BioEscalator officially launches
18 June 2019
Baroness Nicola Blackwood of North Oxford, Parliamentary Under Secretary of State for Innovation, has officially opened the Oxford BioEscalator.
PepGen receives a £1.6M grant from Innovate UK
2 November 2018
PepGen has been awarded a grant of £1.6 M from Innovate UK, the UK’s innovation agency. The company’s project, entitled ‘Application of a novel peptide delivery platform to nucleic acid therapeutics in degenerative and rare diseases’, will run for 20 months, and this funding will be instrumental in supporting the pre-clinical development of PepGen’s innovative technology.
First tenant moves into the BioEscalator
10 September 2018
PepGen is a biotech company that focuses on peptide-mediated delivery of nucleic acids.